VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

ALVAC-RHDV (vCP309) RHDV DNA vaccine pcDNA-VP60 rORFV-RHDV-VP60
Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004738
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: An ALVAC (canarypox)-based recombinant virus ALVAC-RHDV (vCP309) expressing a native rabbit hemorrhagic disease virus (RHDV) capsid protein was derived and assessed for its protective efficacy in rabbits (Fischer et al., 1997).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004577
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Rabbits
  • ORF1 gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: pcDNA3.1(+) (Yuan et al., 2013)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004767
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Rabbit
  • ORF1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: Recombinant Orf virus (ORFV; Parapoxvirus) expressing the major capsid protein VP1 (VP60) of the calicivirus, rabbit hemorrhagic disease virus (RHDV) (Rohde et al., 2011).
    • Detailed Gene Information: Click Here.
  • Preparation: (Rohde et al., 2011) Anew recombinant Orf virus (ORFV; Parapoxvirus) expressing the major capsid protein VP1 (VP60) of RHDV.
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response

Rabbit Response

  • Vaccination Protocol: Rabbits were inoculated with varying doses of vCP309 (Fischer et al., 1997).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Rabbits were challenged with RHDV (Fischer et al., 1997).
  • Efficacy: Protection against a lethal RHDV challenge was demonstrated in rabbits inoculated twice with either high (10(7) p.f.u.) or low (10(5) p.f.u.) doses of vCP309. However, animals in the high dose group developed significantly higher antibody response (Fischer et al., 1997).

Rabbit Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: In all cases, the rabbits immunized with pcDNA-VP60 developed high level of RHDV-specific antibodies and cellular immune response (Yuan et al., 2013).
  • Efficacy: The rabbits inoculated with PBS and pcDNA3.1(+) were not protected from the RHDV challenge and developed high fever and oronasal hemorrhage, and died within two days after challenge as a consequence of the viral infection. All pcDNA-VP60 and RHDV inactive vaccine vaccinated rabbits survived (Yuan et al., 2013).

Rabbit Response

  • Vaccination Protocol: The animals were immunized once, twice or 3-times by the intramuscular (i.m.) route with 1 ml D1701-V-VP1 containing 107 PFU (plaque-forming units), 106 PFU, or 105 PFU, respectively. For controls, groups of rabbits were vaccinated with the commercial RHDV vaccine “RIKA-VACC” (Riemser Arzneimittel AG, Germany) or remained non-vaccinated (Rohde et al., 2011).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Twenty two days after the last vaccination, the animals were inoculated i.m. with 1 ml containing 104 LD50 (lethal dose 50) of the virulent RHDV strain “Eisenhüttenstadt” (Rohde et al., 2011).
  • Efficacy: All animals immunized with the ORFV-vectored vaccine survived without any clinical signs, similar to animals control immunized with the commercially available inactivated RHDV vaccine RIKA-VACC. As expected, all non-immunized rabbits died within 48 h after challenge with RHD-specific clinical symptoms (Rohde et al., 2011).
References References References
Fischer et al., 1997: Fischer L, Le Gros FX, Mason PW, Paoletti E. A recombinant canarypox virus protects rabbits against a lethal rabbit hemorrhagic disease virus (RHDV) challenge. Vaccine. 1997; 15(1); 90-96. [PubMed: 9041672].
Yuan et al., 2013: Yuan D, Qu L, Liu J, Guo D, Jiang Q, Lin H, Si C. DNA vaccination with a gene encoding VP60 elicited protective immunity against rabbit hemorrhagic disease virus. Veterinary microbiology. 2013; 164(1-2); 1-8. [PubMed: 23419819].
Rohde et al., 2011: Rohde J, Schirrmeier H, Granzow H, Rziha HJ. A new recombinant Orf virus (ORFV, Parapoxvirus) protects rabbits against lethal infection with rabbit hemorrhagic disease virus (RHDV). Vaccine. 2011; 29(49); 9256-9264. [PubMed: 22001119].